BioSpace News Archive

CytomX Therapeutics, Inc. announced that John A. Scarlett, M.D. is retiring from its board of directors, effective when his current term expires at the company’s next annual meeting of stockholders, which is currently scheduled to be held on June 15, 2022.

Pasithea Therapeutics Corp. announced its Chief Executive Officer, Tiago Reis Marques, will present at NobleCon18 - Noble Capital Markets’ Eighteenth Annual Investor Conference in Hollywood, FL, as follows:

Intellipharmaceutics International Inc. and, a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, reported the results of operations for the three months ended February 28, 2022.

Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies today announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules with institutional investors for the purchase and sale of 16,226,416 shares of the Company’s common stock.

Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions), today announced that it will release financial results for the first quarter of 2022 after the close of trading on Thursday, May 5, 2022.

DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, will host a conference call and webcast on Tuesday, May 3, 2022 at 5:00 p.m. Eastern Time (ET) to discuss the Company’s first-quarter 2022 operating and financial highlights.

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2022 financial results will be released on Thursday, April 28, after the market closes.

Biohaven Pharmaceutical Holding Company Ltd. announced the publication of new real-world research showing that as migraine-related disability increases, healthcare utilization also increases among Americans with episodic migraine.

AptarGroup, Inc., a global leader in drug delivery, consumer product dispensing and active material science solutions and services, declared a quarterly cash dividend of $0.38 per share.

In the last few years, with the high-end technological advancements on board, there has been a growing inclination toward undergoing minimal invasive surgeries instead of open surgical procedures, by the huge patient pool in the majority of countries.